Effect of Ferric Carboxymaltose on Exercise Capacity in Patients With Iron Deficiency and Chronic Heart Failure

Inclusion Criteria:

• Iron deficient subjects with stable chronic heart failure (CHF) (NYHA II-III) onoptimal background therapy for CHF

• Reduced exercise capacity

• Reduced left ventricular ejection fraction

• At least 18 years of age and with written informed consent prior to any study specificprocedures

Exclusion Criteria:

• Erythropoietin stimulating agent (ESA) use, IV iron therapy, and/or blood transfusionin previous 6 weeks prior to randomisation

• Exercise training program(s) in the 3 months prior to screening or planned in the next 6 months

• Chronic liver disease and/or elevated liver enzymes

• Vitamin B12 and/or serum folate deficiency

• Subject is not using adequate contraceptive precautions during the study

• No other significant cardiac or general disorder that would compromise participationin the study